Upload
christanicholas
View
454
Download
0
Embed Size (px)
DESCRIPTION
Presentation at BIO conference in Chicago May 2010 at "Bootcamp" for biotech entrepreneurs
Citation preview
9711
Christa NicholasDirector
LICENSING, PARTNERING, STRATEGIC ALLIANCES:
ROLE OF AN INTERMEDIATE
9711
GUIDING PRINCIPLE:
BE A GLOBAL COMPANY FROM DAY 1…IF YOU AREN’T, YOUR COMPETITORS ARE!
9711
SUCCESSFUL PARTNERSHIP & STRATEGIC ALLIANCES: IMPACT ON BUSINESS MODEL
Access external resources and capabilities- Clinical and regulatory expertise- “Eyes and ears” on market dynamics
Financial resources- Cash from partnering proceeds- Access to equity capital
Share product development cost/risk Validation of technology (and company)
9711
R&D INVESTMENT VS. NEW DRUG APPROVALS:INNOVATION GAP DRIVES DEAL FLOW
9711
POTENTIAL PARTNERS: BIG PHARMA AND MATURE BIOTECH COMPANIES
9711
CHANGING BUSINESS MODELS
9711
The partnership/alliance should be strategically central to your partner’s business
Internal competing program would not confound decision making
The partner should offer significant added value in R&D capabilities, marketing prowess in key markets (may be a regional market)
Partner has a strong history in successful alliances Good cultural fit, partner values your team’s input “let
the best ideas win!”
SELECTING THE RIGHT PARTNERSHIP, ALLIANCES:IMPORTANT FACTORS
9711
RISK FACTORS OF LICENSING, PARTNERING AND STRATEGIC ALLIANCES
Daunting odds facing all dealmakers- 200+ “real” deals worldwide for >5000 biotech
companies- Average time to complete a deal is ~17 months- False positives throughout the process
Partnering valuation dependent on a wide range of factors- Market and stage of development-related- Franchise fit for partner
Important to recognize that “the process” is: - Demanding - Complicated - Highly relationship- and network-driven- Requiring of the right expertise at the right time
Balance of internal and external resources
9711
79% 73% 74%
8% 11% 8%
14% 15% 18%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2007 2008 2009
Outlicense Co-development, profit sharing(1) "Option" Deals
“OPTION” STRUCTURES GREW IN 2009
Source: Windhover Biopharma and selected Diagnostic deals; Burrill & Co analysisTransactions > $20M announced through 12/31/09(1)Excludes 4 deals with an option to co-develop / profit share in 2007 and 1 in 2008; counted in “Option” Deals category
154 142 131
Total Partnering Transaction Numbers
COMMENTS Generally, upfront
payments are down with the exception of Phase II (where 22 deals produced an average of $55m upfront)
Deal numbers are continuing to trend downward and buyer leverage is increasing;- Co-development and
“profit shares” less frequent
- Option structures on the rise
154 142154 142154
Total Partnering Transaction Numbers142154
9711
PARTNERING MARKET – RECENT OBSERVATIONS Licensees are currently focusing on:
- FDA/regulatory pathway clarity - Strong human PoC data (only exceptions for novel MOAs in high
unmet need areas)- Heightened safety requirements, especially in cardio/metabolic- Generic entry threat- Managed care perception of product value and associated pricing
potential
2009 was a difficult market in which to sell development stage assets; 2010 showing slight improvement - Many potential buyers had insufficient capital to fund their internal
programs- Raising new capital challenging and expensive- Many programs/companies “for sale” – including big uptick in Big
Pharma out-licensing
9711
VALUE OF AN EXPERIENCED INTERMEDIARY Extensive Relationships and Access
– Seasoned senior deal-making team with broad life sciences expertise
– Direct access to the in-licensing universe of CEOs and Chairmen
– Broad distribution capabilities to increase deal competition– Network of relationships allows simultaneous start of all
target companies Deal-Making Acumen
– Leverages team expertise, transactions database and “Horse Race” competitive approach
– Facilitates every step of the deal process, provide appropriate resources to the task
– Shared commitment of two organizations Strong scientific capabilities to assist in presenting
opportunities
9711
PARTNERING, STRATEGIC ALLIANCES: FROM AN INTERMEDIARY’S VIEWPOINT
Good strategy drives good deal-making– Internal value creation– Connection to partner strategic interests
Deal-making requires intensely focused effort– Identify the right mechanism, ideal partner– Manage the deal process
Competition drives success– Getting the deal done– Getting reasonable valuation– Getting a timely outcome
9711
CHOICES OF INTERMEDIARIES: “BEST TEAM” TO ASSIST YOU IN MEETING YOUR STRATEGIC OBJECTIVES
Business development consultants – Management consultants – Free lance seasoned business development
professionals– Therapeutic or geography focused
Boutique banks– Niche focused– Domain expertise (diagnostics, medtech, service sector) – Global or regional
“Investment banks” – Financially focused– Target larger transactions
9711
GOAL: GETTING TO SIGNATURE QUICKLY! Strategy: Ensure licensing, partnering and alliance opportunities
aligned with corporate strategy and therapeutic franchise Execution:
– Introduction of partners– Provide valuable input on presentation and the value proposition– Creation of transaction structures– Coordination of due diligence– Negotiation of term sheets– Management of agreement drafting process– Positioning for corporate approvals– Introduction to funding sources
Address partner requirement and concerns Speed & momentum: establishing a shared culture for
success Implementation of the deal post-signing
Transaction Planning
Definitive AgreementApproach Targets Negotiations,
Due Diligence
9711
TEAM ROLES
CompanyIntermediary
Lead the process Extend company’s business
development capability First point of contact with
prospects Be the “friend of the deal” and
vigorously pursue all means to maximize chances of success
Maintain and manage a “horse race”
Act as a “surrogate partner” to react to, and provide ideas and improvements to Company’s approach
Recommend and win prior sign-off for deal structure and terms
Lead negotiations
Actively engage in the project and contribute to the content
Communicate openly on all aspects of the proejct (positive and negative)
Manage and communicate the process within the organization
Set expectations with BOD Represent and help sell the
technology at key meetings Manage due diligence details Provide/fund legal counsel
9711
GLOBAL COMPANY FROM DAY 1…IF YOU ARE’T, YOUR COMPETITORS ARE!
Compete globally Confidently align with the right partners Creatively resource your company Consult with external experts to maximize the use of
your resources and increase your odds of success